Cerity Partners’s Quest Diagnostics DGX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $7.76M | Sell |
39,590
-2,510
| -6% | -$488K | 0.01% | 821 |
|
|
2025
Q4 | $7.31M | Buy |
42,100
+1,588
| +4% | +$289K | 0.01% | 780 |
|
|
2025
Q3 | $7.72M | Sell |
40,512
-3,345
| -8% | -$594K | 0.01% | 688 |
|
|
2025
Q2 | $7.88M | Buy |
43,857
+1,538
| +4% | +$267K | 0.01% | 624 |
|
|
2025
Q1 | $7.16M | Buy |
42,319
+3,724
| +10% | +$612K | 0.01% | 607 |
|
|
2024
Q4 | $5.85M | Sell |
38,595
-140
| -0.4% | -$21.8K | 0.01% | 653 |
|
|
2024
Q3 | $6.01M | Buy |
38,735
+8,094
| +26% | +$1.21M | 0.01% | 639 |
|
|
2024
Q2 | $4.19M | Buy |
30,641
+161
| +0.5% | +$22K | 0.01% | 659 |
|
|
2024
Q1 | $4.07M | Buy |
30,480
+4,568
| +18% | +$593K | 0.01% | 710 |
|
|
2023
Q4 | $3.57M | Buy |
25,912
+6,678
| +35% | +$878K | 0.01% | 617 |
|
|
2023
Q3 | $2.34M | Sell |
19,234
-1,121
| -6% | -$149K | 0.01% | 545 |
|
|
2023
Q2 | $2.86M | Buy |
20,355
+13,771
| +209% | +$1.9M | 0.01% | 633 |
|
|
2023
Q1 | $1.56M | Sell |
6,584
-153
| -2% | -$21.9K | ﹤0.01% | 803 |
|
|
2022
Q4 | $1.05M | Buy |
6,737
+4,303
| +177% | +$618K | 0.01% | 677 |
|
|
2022
Q3 | $299K | Buy |
2,434
+188
| +8% | +$24.8K | ﹤0.01% | 891 |
|
|
2022
Q2 | $299K | Buy |
2,246
+308
| +16% | +$42K | ﹤0.01% | 908 |
|
|
2022
Q1 | $265K | Sell |
1,938
-738
| -28% | -$103K | ﹤0.01% | 772 |
|
|
2021
Q4 | $466K | Buy |
2,676
+831
| +45% | +$126K | 0.01% | 613 |
|
|
2021
Q3 | $268K | Hold |
1,845
| – | – | 0.01% | 590 |
|
|
2021
Q2 | $243K | Buy |
1,845
+2
| +0.1% | +$262 | 0.01% | 641 |
|
|
2021
Q1 | $237K | Sell |
1,843
-789
| -30% | -$97.2K | 0.01% | 615 |
|
|
2020
Q4 | $314K | Sell |
2,632
-716
| -21% | -$87.3K | 0.01% | 504 |
|
|
2020
Q3 | $383K | Buy |
3,348
+601
| +22% | +$71K | 0.02% | 361 |
|
|
2020
Q2 | $313K | Buy |
2,747
+143
| +5% | +$15.2K | 0.02% | 346 |
|
|
2020
Q1 | $209K | Buy |
2,604
+474
| +22% | +$49.1K | 0.01% | 406 |
|
|
2019
Q4 | $227K | Buy |
+2,130
| New | +$222K | 0.01% | 484 |
|
|
2019
Q2 | – | Sell |
-2,294
| Closed | -$206K | – | 507 |
|
|
2019
Q1 | $206K | Buy |
+2,294
| New | +$199K | 0.01% | 500 |
|
|
2018
Q4 | – | Sell |
-2,341
| Closed | -$253K | – | 522 |
|
|
2018
Q3 | $253K | Sell |
2,341
-134
| -5% | -$14.7K | 0.02% | 458 |
|
|
2018
Q2 | $272K | Buy |
+2,475
| New | +$258K | 0.02% | 442 |
|
Other funds holding DGX
VCM
VPM
EIG
Cerity Partners's DGX Position: Q1 2026 in Review
Cerity Partners reduced its Quest Diagnostics (DGX) stake by 6% in Q1 2026, selling an estimated $488K and leaving 39,590 shares worth $7.76M. The position accounts for 0.01% of the portfolio, ranked #821.
Cerity Partners first reported a position in DGX in Q2 2018 and has held it in 29 quarters since. The position peaked at $7.88M in Q2 2025. 1,063 funds tracked by Wall St. Rank hold DGX as of Q1 2026.
- Cerity Partners held 39,590 shares of Quest Diagnostics worth $7.76M as of Q1 2026.
- Cerity Partners sold 2,510 Quest Diagnostics shares in Q1 2026, an estimated $488K.
- Quest Diagnostics made up 0.01% of Cerity Partners's portfolio in Q1 2026, its #821 holding.
- Cerity Partners first reported a position in Quest Diagnostics in Q2 2018 and has held it in 29 quarters since.
- Cerity Partners's Quest Diagnostics position peaked at $7.88M in Q2 2025.
- 1,063 funds tracked by Wall St. Rank held Quest Diagnostics as of Q1 2026.
Based on Cerity Partners's 13F filing for Q1 2026, filed 15 May 2026.